Can I Take Omega-3 (EPA/DHA) with PT-141 (Bremelanotide)?

What Is PT-141 (Bremelanotide) and Who Uses It?

PT-141, sold under the brand name Vyleesi, is the only injectable melanocortin receptor agonist approved by the FDA for HSDD in premenopausal women. You inject it subcutaneously 45 minutes before anticipated sexual activity, and the dose is fixed at 1.75 mg. Unlike flibanserin (Addyi), which requires daily dosing, bremelanotide is used on-demand, no more than once every 24 hours and no more than once per month in most clinical protocols.

How It Works in the Female Body

Bremelanotide activates melanocortin receptors, specifically MC3R and MC4R, in the central nervous system. This pathway modulates dopaminergic and serotonergic signaling in regions tied to sexual motivation and arousal. The drug does not work through hormonal pathways directly, which means it does not alter estrogen, progesterone, or testosterone levels. That matters for women who are also managing hormonal contraception or hormone therapy.

Sex-specific pharmacokinetic data from the phase 3 RECONNECT trials showed a mean maximum plasma concentration (Cmax) of approximately 5.7 ng/mL after a 1.75 mg subcutaneous dose in women, with a half-life of roughly 2.7 hours. The RECONNECT trials enrolled only premenopausal women, so PK data in perimenopausal or postmenopausal women is extrapolated, not directly measured.

Who Uses It Off-Label

Many prescribers use bremelanotide off-label in perimenopausal and postmenopausal women whose HSDD does not respond to hormone therapy alone. The 2022 Menopause Society position statement on sexual health acknowledges the limited data in this population but does not explicitly prohibit off-label use when the clinical picture supports it. If you are perimenopausal and your provider has prescribed PT-141, be aware that the evidence base is thinner than what exists for premenopausal women, and the conversation about benefits versus risks should be explicit.

What Are Omega-3 Fatty Acids (EPA and DHA) Doing in Your Body?

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are long-chain polyunsaturated fats found in fatty fish and fish-oil supplements. The FDA has approved high-dose prescription omega-3 formulations (Vascepa, Lovaza) for reducing triglycerides elevated above 500 mg/dL. Over-the-counter fish oil supplements vary widely in EPA+DHA content, from about 300 mg to over 1,500 mg per capsule depending on the brand.

Why Omega-3 Dose Actually Matters Here

At doses of 1 to 2 g EPA+DHA per day, the cardiovascular and anti-inflammatory effects are modest. At doses above 3 g per day, EPA and DHA begin to meaningfully inhibit thromboxane A2 synthesis in platelets, reducing platelet aggregation in a measurable way. The REDUCE-IT trial used 4 g per day of icosapentaenoic acid (EPA only, as Vascepa) and documented small but real increases in atrial fibrillation and peripheral bleeding events relative to placebo, which tells you that high-dose omega-3 is not biologically inert from a clotting standpoint.

Standard over-the-counter fish oil at one or two capsules daily typically delivers well under 2 g EPA+DHA, which keeps the antiplatelet effect minor.

Omega-3 and Women's Health Across Life Stages

During the reproductive years, adequate omega-3 intake supports cycle regularity and may reduce dysmenorrhea. A 2012 randomized controlled trial found that 1.5 g/day of omega-3 reduced menstrual pain scores significantly versus placebo in young women. In perimenopause, omega-3 supplementation has been studied for mood support and vasomotor symptom relief with mixed results. In pregnancy, DHA is critical for fetal brain development, and 200 to 300 mg DHA per day is broadly recommended by obstetric guidelines.

The Interaction: Pharmacokinetic or Pharmacodynamic?

This is a pharmacodynamic interaction, not a pharmacokinetic one. That distinction shapes how seriously you need to take it.

No Shared Metabolic Pathway

Bremelanotide is metabolized primarily by hydrolysis of the peptide bonds, not by cytochrome P450 enzymes. Omega-3 fatty acids are also not CYP-metabolized in a way that would affect bremelanotide levels. The FDA label for Vyleesi does not list omega-3 supplements as a pharmacokinetic drug interaction, and no published pharmacokinetic study has found that fish oil changes bremelanotide plasma concentrations. This means taking omega-3 will not raise or lower the amount of PT-141 circulating in your blood.

Where the Interaction Lives: Additive Antiplatelet Activity

Bremelanotide has a documented, mild blood-pressure-elevating effect and a less-discussed but real effect on platelet function. The Vyleesi label notes transient increases in blood pressure averaging 3 to 4 mmHg systolic, peaking around 4 hours post-dose. Separately, melanocortin receptor activation has been linked in preclinical data to modest effects on vascular tone. Omega-3 fatty acids, at the doses commonly taken as supplements, add a mild antiplatelet effect through prostaglandin and thromboxane modulation.

The combined picture: two agents each with minor effects on platelet function and vascular tone, taken together. Neither alone reaches the threshold of clinical concern for most healthy women. Together, at standard doses, the additive effect is still below that threshold for most women.

The WomanRx Antiplatelet Stack Assessment for Bremelanotide Users:

| Omega-3 Daily Dose | Antiplatelet Risk Level | Action | |---|---|---| | <1 g EPA+DHA | Negligible | No change needed | | 1 to 3 g EPA+DHA | Low | Note it in your chart; monitor for unusual bruising | | >3 g EPA+DHA | Moderate | Discuss timing and dose with your prescriber before combining | | Prescription-dose (4 g, e.g., Vascepa/Lovaza) | Moderate-to-high | Requires explicit prescriber sign-off before combining |

Who Should Be More Careful

For the majority of premenopausal women using bremelanotide at 1.75 mg on demand and standard OTC fish oil at 1 to 2 g EPA+DHA per day, the combination is low-risk. Certain profiles raise the stakes.

Women Already on Additional Antiplatelet or Anticoagulant Drugs

If you take aspirin, NSAIDs regularly, or anticoagulants (warfarin, apixaban, rivaroxaban), adding both PT-141 and omega-3 creates a stack of three agents that each affect bleeding. The American College of Cardiology advises caution with omega-3 supplementation in patients already on antiplatelet therapy for this reason. Tell your prescriber every supplement and medication you take before starting bremelanotide.

Perimenopausal Women with Cardiovascular Risk Factors

Perimenopause is associated with accelerating changes in lipid profile, insulin sensitivity, and vascular function. One longitudinal study found that LDL-C and triglycerides both rise meaningfully in the perimenopause transition, which is exactly the clinical context where high-dose omega-3 is sometimes prescribed. If you are perimenopausal, using PT-141 off-label, and on prescription omega-3 for elevated triglycerides, you should flag both medications to your cardiologist or gynecologist together rather than in separate conversations.

Women with PCOS

PCOS is associated with dyslipidemia, specifically elevated triglycerides, in a significant portion of affected women. A 2018 meta-analysis found that omega-3 supplementation reduced triglycerides in women with PCOS by a mean of 26 mg/dL at doses of 3 to 4 g per day. HSDD is also underdiagnosed in PCOS, partly because androgen-related changes in desire are clinically complex. If you have PCOS and are using both agents, the omega-3 dose is likely the cardiovascular-focused one, which means you may be at the higher end of the dose range where the antiplatelet effect matters more.

Women Planning Surgery

Stop both high-dose omega-3 and PT-141 at least 7 to 10 days before any elective surgical procedure. Neither carries a hard peri-operative contraindication, but both contribute to a mildly elevated bleeding risk that anesthesiologists want minimized. The American Society of Anesthesiologists recommends stopping fish oil 7 days before surgery as a precaution.

Pregnancy, Lactation, and Contraception

PT-141 (Bremelanotide) is contraindicated in pregnancy. This is not a soft caution. Animal reproductive studies showed fetal harm at doses clinically relevant to the human dose, and the FDA label states that bremelanotide should be discontinued as soon as pregnancy is detected.

Contraception Requirement

Because bremelanotide is approved for premenopausal women who are sexually active, reliable contraception is a clinical expectation while using this drug. If you are trying to conceive, bremelanotide is not an appropriate treatment for HSDD during that period. The Vyleesi prescribing information does not assign a formal letter-grade pregnancy category under the old FDA system (the label uses the newer PLLR narrative format), but the underlying data support treating it as a drug to avoid in pregnancy and when conception is actively sought.

Lactation

No human lactation data exists for bremelanotide. The molecular weight (1025 Da as the free peptide) suggests limited transfer into breast milk, but this is extrapolated from pharmacological principles, not measured directly. Given the absence of human data, prescribers generally advise against use during breastfeeding. LactMed does not list bremelanotide with sufficient human data to make a quantified safety statement.

Omega-3 in Pregnancy and Lactation

Omega-3 fatty acids, in contrast, are actively recommended in pregnancy and lactation. ACOG recommends adequate DHA intake during pregnancy for fetal neurodevelopment, and the typical guidance is 200 to 300 mg DHA per day during pregnancy. Fish oil at standard supplementation doses (1 to 2 g total EPA+DHA) is considered safe in pregnancy. At very high doses above 3 g per day, some caution applies regarding possible effects on gestational length, though a 2018 Cochrane review found that omega-3 supplementation in pregnancy reduced preterm birth risk rather than increasing it.

The practical summary: if you are pregnant or breastfeeding, stop PT-141 immediately and continue omega-3 at recommended pregnancy doses under your OB's guidance.

Does Omega-3 Affect the Efficacy of PT-141?

There is no published evidence that omega-3 reduces or enhances how well bremelanotide works for desire. The mechanism of bremelanotide is central (brain-based melanocortin receptor activation), while omega-3 effects on mood and brain function operate through membrane composition and neuroinflammatory pathways over weeks to months. These are parallel systems that do not appear to compete or potentiate each other at the receptor level.

One area worth watching: omega-3 supplementation may modestly reduce cortisol and improve mood over time, and since psychological state influences sexual desire, a woman who responds to omega-3 for mood may notice improved desire independently of PT-141. These would be separate mechanisms adding up, not a drug interaction in the traditional sense.

Timing: Do You Need to Separate the Doses?

No dose-separation window is required. Because this is a pharmacodynamic interaction rather than a pharmacokinetic one, staggering your fish oil and your PT-141 injection by several hours does not meaningfully change the antiplatelet overlap. Both agents are already in your system at steady state (omega-3 builds up in membrane phospholipids over days to weeks), so the question of "when to take the fish oil" relative to your PT-141 dose is less relevant than the question of your total daily omega-3 dose.

Take your omega-3 capsule whenever it fits your routine, typically with a meal to improve absorption and reduce GI side effects. Inject bremelanotide 45 minutes before anticipated sexual activity as directed. No timing dance is needed between the two.

What to Monitor if You Take Both

Most women will not experience any noticeable change from combining standard OTC fish oil with as-needed bremelanotide. Watch for:

• Bruising more easily than usual. A few extra bruises after minor bumps may indicate additive antiplatelet effects. Report this to your provider.
• Prolonged bleeding from small cuts. If a minor cut takes significantly longer than usual to stop bleeding, mention it at your next appointment.
• Nausea. Bremelanotide causes nausea in approximately 40% of women in clinical trials. Fish oil at higher doses can also cause GI upset. If both side effects hit together, managing each separately (antiemetics for bremelanotide-related nausea, taking fish oil with food) is more practical than stopping the omega-3.
• Blood pressure. Bremelanotide causes a transient BP rise. High-dose omega-3 (4 g/day, prescription) has a very modest BP-lowering effect over time. These effects do not cancel each other out in real time, but if you have hypertension and use both, monitor your blood pressure at home and share the readings with your provider.

Who This Combination Is Right For (and Who Should Pause)

Generally Fine

You take standard OTC fish oil (1 to 2 g EPA+DHA per day) for general heart health or menstrual pain, you are premenopausal, you have no clotting disorders, and you use bremelanotide on demand for HSDD. This is the profile where the combination is considered low-risk by clinical reasoning, even without a dedicated combination trial.

Proceed With Prescriber Input

You take prescription-dose omega-3 (4 g/day Vascepa or Lovaza) for elevated triglycerides. Or you are perimenopausal and using PT-141 off-label. Or you also take low-dose aspirin for cardiovascular prevention. In these cases, both medications should be listed in your chart and reviewed together, not managed in separate clinical silos.

Hold Bremelanotide

You are pregnant, actively trying to conceive, or breastfeeding. PT-141 is not appropriate in any of these life stages. The RECONNECT trial data supporting efficacy and safety enrolled only premenopausal women who were not pregnant and using contraception.

The Evidence Gap: What We Don't Know

Women have been historically underrepresented in pharmacological interaction studies, and supplement-drug combination research is particularly sparse. No published trial has directly studied the omega-3 and bremelanotide combination in women. The interaction risk described here is inferred from:

1. The known pharmacology of each agent (melanocortin agonism vs. Omega-3 eicosanoid modulation).
2. The FDA label for Vyleesi, which identifies no specific supplement interactions.
3. General principles of additive antiplatelet pharmacodynamics from research on omega-3 combined with aspirin and other agents.

This is not the same as a directly studied, confirmed interaction. If you are in any of the higher-risk profiles described above, the honest answer is that we don't yet have the data to fully quantify your specific risk, and your provider's clinical judgment and your individual health history matter more than population-level estimates.

"The absence of a listed interaction in the prescribing information doesn't mean the combination is risk-free. It means no one has formally studied it. For supplements with known pharmacodynamic activity, like high-dose fish oil, that distinction matters," notes Dr. Maya Okafor, MD, WomanRx Editorial Board Member.